JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [4][6]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Jasper to contact them, highlighting a deadline of November 18, 2025, for seeking the role of lead plaintiff in a federal securities class action against the company [4][8]. Allegations Against Jasper - The complaint alleges that Jasper and its executives made false and misleading statements, failing to disclose critical issues regarding their manufacturing processes and the implications for their product, briquilimab [6]. - Specific allegations include: - Lack of necessary controls for third-party manufacturers to comply with cGMP regulations [6]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects [6]. - Overstated business and financial prospects due to these failures [6]. Stock Price Impact - Following a press release on July 7, 2025, which revealed significant issues with a drug product lot and the halting of several studies, Jasper's stock price plummeted by $3.73 per share, or 55.1%, closing at $3.04 per share [7].